Medicines Co. sees Q2 income gains on strong Angiomax sales

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The Medicines Company has announced an increase in its financial outcome for the second quarter of 2010, which ended June 30.

Net income was $15.4 million, compared with net income of $3.8 million for the second quarter 2009, according to the Parsippany, N.J.-based company. Its total net revenue increased to $110.1 million for the second quarter from $104.2 million for the second quarter 2009.

For its U.S. bivalirudin (Angiomax) sales, The Medicines Company said sales increased to $104.4 million compared with $98.8 million for the second quarter 2009. However, its international sales also increased—Angiomax/Angiox international net revenue increased to $5.8 million compared with $4.5 million for the second quarter 2009.